Screener
AbCellera Biologics Inc. ABCL EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | Three months ended June 30, 2025 | Three months ended June 30, 2026 | Six months ended June 30, 2025 | Six months ended June 30, 2026 |
|---|---|---|---|---|
| Foreign currency translation adjustment | 4,341 | (733) | 1,721 | 1,082 |
| Comprehensive loss | $(30,386) | $(56,160) | $(78,627) | $(97,510) |
| Net loss per share | ||||
| Basic | $(0.12) | $(0.18) | $(0.27) | $(0.32) |
| Diluted | $(0.12) | $(0.18) | $(0.27) | $(0.32) |
| Weighted-average common shares outstanding | ||||
| Basic | 298,508,601 | 305,557,294 | 298,105,760 | 304,329,623 |
| Diluted | 298,508,601 | 305,557,294 | 298,105,760 | 304,329,623 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s EPS (basic)?
- AbCellera Biologics Inc. (ABCL) reported EPS (basic) of -$0.18 in Q2 2026.
- How has AbCellera Biologics Inc.'s EPS (basic) changed year-over-year?
- AbCellera Biologics Inc.'s EPS (basic) decreased by 50.0% year-over-year, from -$0.12 to -$0.18.
- What is the long-term trend for AbCellera Biologics Inc.'s EPS (basic)?
- Over 3 years (2021 to 2025), AbCellera Biologics Inc.'s EPS (basic) has grown at a -4.4% compound annual growth rate (CAGR), from $0.56 to -$0.49.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about AbCellera Biologics Inc.'s eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude